Background and Objectives
A global pharma company needed to make strategic choices to acquire their next IO targets.
SmartAnalyst adopted the following approach to accomplish the objectives:
Conducted secondary research to map the IO universe and pre-screened the long list of pre-clinical and clinical IO targets (208) and shortlisted 25 targets for evaluation and prioritization, based on client-specific parameters.
Organized an Ad Board with external experts to support the evaluation and prioritization of the shortlisted targets.
Evaluated shortlisted targets, of which five were prioritized as ‘high’ based on
- Role in cancer biology and cancer immunity cycle
- Prognostic significance
- Rate of aberration
Non trivial clinical evidence
In vivo evidence
Potential combinability of select targets with other novel IO targets
High level commercial considerations: Breadth of applicability across tumors, competitive intensity and time to market.
SmartAnalyst identified the five most attractive IO targets, based on biologic and scientific rationale and high-level commercial considerations and developed detailed target profiles. This helped the company to frame its strategy for acquisition of IO targets.
About SmartAnalyst: Driving pipeline and portfolio value for global biopharma and life science companies
SmartAnalyst helps biopharma companies make key decisions at the Disease, Asset, and Portfolio levels, utilizing our proprietary strategic frameworks.
We provide comprehensive, integrated solutions based on our deep understanding of the science, the market, and the key business decisions that our client's face. We deploy agile, cross-functional project teams that are responsive to the client needs.